These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

897 related articles for article (PubMed ID: 33910164)

  • 1. A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with
    Qin S; Yu Y; Guan H; Yang Y; Sun F; Sun Y; Zhu J; Xing L; Yu J; Sun X
    Aging (Albany NY); 2021 Apr; 13(9):13006-13022. PubMed ID: 33910164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET Imaging of Tumor PD-L1 Expression with a Highly Specific Nonblocking Single-Domain Antibody.
    Lv G; Sun X; Qiu L; Sun Y; Li K; Liu Q; Zhao Q; Qin S; Lin J
    J Nucl Med; 2020 Jan; 61(1):117-122. PubMed ID: 31253743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of novel peptide-based radiotracers for detecting PD-L1 expression and guiding cancer immunotherapy.
    Zhu S; Liang B; Zhou Y; Chen Y; Fu J; Qiu L; Lin J
    Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):625-640. PubMed ID: 37878029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical Study of a Fully Human Anti-PD-L1 Antibody as a Theranostic Agent for Cancer Immunotherapy.
    Xu M; Han Y; Liu G; Xu Y; Duan D; Liu H; Du F; Luo P; Liu Z
    Mol Pharm; 2018 Oct; 15(10):4426-4433. PubMed ID: 30133286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immuno-PET imaging of
    Liu Q; Jiang L; Li K; Li H; Lv G; Lin J; Qiu L
    Cancer Immunol Immunother; 2021 Jun; 70(6):1721-1733. PubMed ID: 33386467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose escalation biodistribution, positron emission tomography/computed tomography imaging and dosimetry of a highly specific radionuclide-labeled non-blocking nanobody.
    Yang Y; Wang C; Wang Y; Sun Y; Huang X; Huang M; Xu H; Fan H; Chen D; Zhao F
    EJNMMI Res; 2021 Oct; 11(1):113. PubMed ID: 34718889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical evaluation and pilot clinical study of [
    Ma X; Zhou X; Hu B; Li X; Yao M; Li L; Qin X; Li D; Yao Y; Hou X; Liu S; Chen Y; Wang Z; Zhou W; Li N; Zhu H; Jia B; Yang Z
    Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):3838-3850. PubMed ID: 37555904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Vivo Evaluation and Dosimetry Estimate for a High Affinity Affibody PET Tracer Targeting PD-L1.
    Rubins DJ; Meng X; McQuade P; Klimas M; Getty K; Lin SA; Connolly BM; O'Malley SS; Haley H; Purcell M; Gantert L; Holahan M; Lindgren J; Eklund P; Ekblad C; Frejd FY; Hostetler ED; González Trotter DE; Evelhoch JL
    Mol Imaging Biol; 2021 Apr; 23(2):241-249. PubMed ID: 33098025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linear Peptide-Based PET Tracers for Imaging PD-L1 in Tumors.
    Zhang L; Zhang S; Wu J; Wang Y; Wu Y; Sun X; Wang X; Shen J; Xie L; Zhang Y; Zhang H; Hu K; Wang F; Wang R; Zhang MR
    Mol Pharm; 2023 Aug; 20(8):4256-4267. PubMed ID: 37368947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of small-molecular-based radiotracers for PET imaging of PD-L1 expression and guiding the PD-L1 therapeutics.
    Yang H; Zeng X; Liu J; Wen X; Liu H; Liang Y; Wang X; Fang J; Zhang Q; Li J; Zhang X; Guo Z
    Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1582-1592. PubMed ID: 38246910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immuno-PET imaging of PD-L1 expression in patient-derived lung cancer xenografts with [
    Liu Q; Wang X; Yang Y; Wang C; Zou J; Lin J; Qiu L
    Quant Imaging Med Surg; 2022 Jun; 12(6):3300-3313. PubMed ID: 35655844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Checkpoint Inhibition Followed by Tumor Infiltration of Dendritic Cells in Murine Neuro-2a Neuroblastoma.
    Inoue S; Horiuchi Y; Setoyama Y; Takeuchi Y; Beck Y; Murakami T; Odaka A
    J Surg Res; 2020 Sep; 253():201-213. PubMed ID: 32380346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD4
    Kristensen LK; Fröhlich C; Christensen C; Melander MC; Poulsen TT; Galler GR; Lantto J; Horak ID; Kragh M; Nielsen CH; Kjaer A
    Theranostics; 2019; 9(26):8221-8238. PubMed ID: 31754392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging.
    Mayer AT; Natarajan A; Gordon SR; Maute RL; McCracken MN; Ring AM; Weissman IL; Gambhir SS
    J Nucl Med; 2017 Apr; 58(4):538-546. PubMed ID: 27980047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo positron emission tomography imaging for PD-L1 expression in cancer using aptamer.
    Choi YJ; Park JY; Cho YL; Chae JR; Cho H; Kang WJ
    Biochem Biophys Res Commun; 2022 Sep; 620():105-112. PubMed ID: 35780578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and Preclinical Evaluation of a
    Robu S; Richter A; Gosmann D; Seidl C; Leung D; Hayes W; Cohen D; Morin P; Donnelly DJ; Lipovšek D; Bonacorsi SJ; Smith A; Steiger K; Aulehner C; Krackhardt AM; Weber WA
    J Nucl Med; 2021 Sep; 62(9):1228-1234. PubMed ID: 33517324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Probody Therapeutic Design of
    Giesen D; Broer LN; Lub-de Hooge MN; Popova I; Howng B; Nguyen M; Vasiljeva O; de Vries EGE; Pool M
    Clin Cancer Res; 2020 Aug; 26(15):3999-4009. PubMed ID: 31953313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multifunctional Probe Based on "Chemical Antibody-Aptamer" for Noninvasive Detection of PD-L1 Expression in Cancer.
    Kong S; Liu Q; Chen Y; Liang B; Zhou Y; Lin J; Xie M; Qiu L
    Mol Pharm; 2024 Jan; 21(1):255-266. PubMed ID: 38093483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Vivo Imaging of the Programmed Death Ligand 1 by
    González Trotter DE; Meng X; McQuade P; Rubins D; Klimas M; Zeng Z; Connolly BM; Miller PJ; O'Malley SS; Lin SA; Getty KL; Fayadat-Dilman L; Liang L; Wahlberg E; Widmark O; Ekblad C; Frejd FY; Hostetler ED; Evelhoch JL
    J Nucl Med; 2017 Nov; 58(11):1852-1857. PubMed ID: 28588151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies.
    Huang A; Peng D; Guo H; Ben Y; Zuo X; Wu F; Yang X; Teng F; Li Z; Qian X; Qin FX
    Sci Rep; 2017 Feb; 7():42687. PubMed ID: 28202921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.